Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 18/11/2021, Revision: 5, Status: Authorised
TO: